212
Participants
Start Date
February 26, 2024
Primary Completion Date
February 28, 2026
Study Completion Date
February 28, 2026
Tamsulosin
"Tamsulosin is a selective antagonist at alpha-1A and alpha-1B-adrenoreceptors in the prostate, prostatic capsule, prostatic urethra, and bladder neck. Blockage of the alpha-1A receptors causes relaxation of smooth muscles in the bladder neck and prostate, thus decreasing urinary outflow resistance in men.~Tamsulosin will be administered twice a day for two (2) days as an oral tablet containing 0.4 mg of the drug. It is usually administered 30 minutes after a meal to minimize plasma level variations. The 0.4 mg dose of tamsulosin that will be used in this trial has shown adequate safety and tolerability in multiple previously published studies as well as efficacy in treating benign prostatic hyperplasia (BPH) and lower urinary tract symptoms in men.~A Foley catheter, which will be placed for the participant's surgical procedure regardless of enrollment in the study, will be removed at midnight on postoperative day 1."
Control Group
A Foley catheter, which will be placed for the participant's surgical procedure regardless of enrollment in the study, will be removed at midnight on postoperative day 1.
RECRUITING
Emory Saint Joseph's Hospital, Atlanta
RECRUITING
Emory University Hospital Midtown, Atlanta
RECRUITING
Emory University Hospital (EUH), Atlanta
ABRAHAM J & PHYLLIS KATZ FOUNDATION
UNKNOWN
Emory University
OTHER